111 Inc (YI)
NASDAQ:YI
Want to see YI full AI Analyst Report?
Top Page
111
(NASDAQ:YI)
Select Model
Select Model
Rating:43Neutral
Price Target:
$6.00
▲(110.53% Upside)
Action:Reiterated
Date:05/03/26
The score is held down primarily by a stressed financial profile—declining revenue, very thin gross margins, and a balance sheet with negative equity—despite a meaningful improvement in cash generation and reduced losses. Technically, momentum is weak with the price below key moving averages and a negative MACD, although oversold indicators offer only limited support. Valuation is hard to assess with a negative P/E and no dividend data.
Positive Factors
Improved Cash Generation
The shift to positive operating and free cash flow in 2024–2025 materially improves near-term self-funding. Durable cash generation reduces reliance on equity/debt raises, supports working capital and execution of strategic initiatives, and provides a runway to solidify operational recovery.
Negative Factors
Declining Revenue Trend
Persistent top-line decline erodes scale advantages in distribution and retail, weakening bargaining power with suppliers and partners. Lower volumes make fixed-cost absorption harder, threatening long-term margin gains and forcing continued cost-cutting or asset sales to protect profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved Cash Generation
The shift to positive operating and free cash flow in 2024–2025 materially improves near-term self-funding. Durable cash generation reduces reliance on equity/debt raises, supports working capital and execution of strategic initiatives, and provides a runway to solidify operational recovery.
Read all positive factors
111 (YI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$50.34M
Dividend YieldN/A
Average Volume (3M)22.80K
Price to Earnings (P/E)―
Beta (1Y)0.56
Revenue Growth-12.80%
EPS Growth-1.34%
CountryUS
Employees1,238
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)-8.56
Shares Outstanding5,067,436
10 Day Avg. Volume15,490
30 Day Avg. Volume22,804
Financial Highlights & Ratios
PEG Ratio6.95
Price to Book (P/B)-0.22
Price to Sales (P/S)0.01
P/FCF Ratio1.36
Enterprise Value/Market Cap-0.14
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda23.52
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)$17.20B
111 Business Overview & Revenue Model
Company Description
111, Inc. operates an integrated online and offline platform in the healthcare market in the People's Republic of China. It operates through two segments, B2B and B2C. The company sells medical and wellness products through online retail, and whol...
How the Company Makes Money
111, Inc. primarily makes money through the sale and distribution of pharmaceuticals and healthcare products via its integrated online and offline channels. Revenue is generated from (1) product sales to pharmacies, clinics, and other healthcare p...
111 Earnings Call Summary
Earnings Call Date:Mar 20, 2025
(Q4-2024)
| % Change Since: |
Next Earnings Date:Aug 20, 2026
Earnings Call Sentiment Positive
The earnings call demonstrates significant achievements in operational profitability and cost reduction despite challenging macroeconomic conditions and regulatory changes. The company's advancements in technology and supply chain expansion position it well for future growth, though market and competitive pressures remain.Positive Updates
First Ever Operational Profitability
111 achieved its first ever operational profitability and positive operating cash flow in 2024, marking a significant milestone in the company's history.
Negative Updates
Macroeconomic Challenges in China
Economic uncertainties and healthcare reforms in China have led to cautious consumer behavior, affecting retail sales and healthcare expenditure growth.
Read all updates
Q4-2024 Updates
Positive
Negative
First Ever Operational Profitability
111 achieved its first ever operational profitability and positive operating cash flow in 2024, marking a significant milestone in the company's history.
Read all positive updates
Company Guidance
During the conference call held on March 20, 2025, the management of 111 provided insights into their fiscal year 2024 performance and future outlook. Despite macroeconomic challenges and healthcare reforms impacting the industry, 111 achieved its first-ever operational profitability and positive operating cash flow. The company reduced operating expenses by 31% year-over-year, bringing them down to 5.7% of revenues. Key financial highlights included a yearly profit from operations of RMB2.1 million, a turnaround from a RMB350.1 million operational loss in 2023, and a non-GAAP income from operations of RMB22.3 million. The company also highlighted advancements in technology and supply chain infrastructure, such as their decentralized inventory network and AI-driven demand forecasting, which significantly improved operational efficiency. Looking ahead, 111 plans to leverage AI and digital transformation to enhance customer engagement and operational efficiency, aiming to capitalize on China's evolving healthcare market and structural trends like the aging population and healthcare transparency reforms.111 Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
18
Very Negative
Cash Flow
46
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 14.18B | 12.21B | 14.40B | 14.95B | 13.52B | 12.43B |
| Gross Profit | 793.57M | 703.70M | 829.23M | 848.98M | 839.98M | 621.10M |
| EBITDA | -296.00K | -10.03M | 24.62M | -311.26M | -321.81M | -588.32M |
| Net Income | -74.15M | -16.84M | -64.74M | -392.69M | -416.88M | -669.81M |
Balance Sheet | ||||||
| Total Assets | 2.48B | 2.20B | 2.79B | 3.09B | 3.47B | 3.15B |
| Cash, Cash Equivalents and Short-Term Investments | 447.47M | 611.72M | 462.29M | 653.67M | 879.53M | 843.95M |
| Total Debt | 212.93M | 217.73M | 256.77M | 443.23M | 344.19M | 491.01M |
| Total Liabilities | 2.15B | 1.99B | 2.41B | 2.81B | 2.83B | 2.30B |
| Stockholders Equity | -673.07M | -702.68M | -642.64M | -583.45M | -414.60M | -173.32M |
Cash Flow | ||||||
| Free Cash Flow | 97.31M | 114.69M | 247.82M | -457.07M | -54.73M | -751.53M |
| Operating Cash Flow | 112.51M | 119.14M | 263.02M | -447.24M | -23.15M | -688.84M |
| Investing Cash Flow | 86.05M | -53.72M | 37.38M | 151.74M | -47.17M | 60.14M |
| Financing Cash Flow | -200.60M | -21.19M | -406.24M | 205.98M | 22.73M | 74.34M |
111 Technical Analysis
Negative
2.85
Price Trends
6.38
Negative
6.26
Negative
5.55
Negative
Market Momentum
-0.23
Positive
36.30
Neutral
16.90
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For YI, the sentiment is Negative. The current price of 2.85 is below the 20-day moving average (MA) of 6.04, below the 50-day MA of 6.38, and below the 200-day MA of 5.55, indicating a bearish trend. The MACD of -0.23 indicates Positive momentum. The RSI at 36.30 is Neutral, neither overbought nor oversold. The STOCH value of 16.90 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for YI.
111 Risk Analysis
111 disclosed 83 risk factors in its most recent earnings report. 111 reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
If the PCAOB is prevented from fully evaluating audits and quality control procedures of our auditor, investors may be deprived of the benefits of such PCAOB inspections. Q4, 2023
2.
It may be difficult for regulators to conduct cross-border investigation. Q4, 2023
3.
An outbreak of disease or similar public health threat, or fear of such an event, could have a material adverse impact on our business, operating results and financial condition Q4, 2023
111 Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $26.64M | -7.51 | -1538.29% | ― | ― | ― | |
49 Neutral | $32.37M | >-0.01 | -4587.82% | ― | -30.75% | -1056.69% | |
47 Neutral | $26.88M | -3.82 | -695.82% | ― | 7.13% | -8.85% | |
47 Neutral | $82.94M | -1.69 | -258.45% | ― | ― | 33.42% | |
46 Neutral | $52.17M | -1.51 | -560.64% | ― | -32.64% | 56.66% | |
43 Neutral | $50.34M | -6.67 | 8.26% | ― | -12.80% | -1.34% |
* Healthcare Sector Average
YI
111
5.70
-2.23
-28.12%
RMTI
Rockwell Med
0.79
-0.19
-19.00%
DYAI
Dyadic International
0.76
-0.24
-23.72%
RNTX
Rein Therapeutics
1.03
-1.02
-49.76%
ELUT
Elutia
1.16
-0.56
-32.56%
NEUP
Neuphoria Therapeutics
5.48
-1.30
-19.17%
111 Corporate Events
111, Inc. Posts 2025 Profitability Milestone as Asset-Light Pivot Lifts Margins
Apr 9, 2026
On April 9, 2026, 111, Inc. reported unaudited results for the fourth quarter and full year ended December 31, 2025, highlighting a pivotal shift to an asset-light warehouse partnership model that included divesting several subsidiaries and re-eng...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.